Imugene (IMU) Fundamentals 2026 — Revenue Analysis | SniperIQ
Imugene (IMU) is a AU-listed Healthcare company in Biotechnology with a market capitalization of A
Imugene (IMU) has a market capitalization of approximately A
Imugene's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Imugene runs a net profit margin of -1864.1%, a gross margin of -65.9%, and an operating margin of -1960.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Imugene reported revenue of A$4M for fiscal year 2025, with net income of -A$69M and earnings per share (EPS) of -0.32. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Imugene does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Imugene carries a debt-to-equity ratio of 0.12x and a current ratio of 1.78x, with a market beta of 2.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Imugene (IMU) the key facts are: market cap A
Get Imugene's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.